TGR BioSciences Announces Expansion of its ‘No-Wash’ SureFire® Cellular Kinase Assay Portfolio

ADELAIDE, Australia–TGR BioSciences announces expansion of the extremely successful and proven ‘No-wash’ SureFire® portfolio by addition of 9 new cell pathway analysis kits for measurement of phospho-proteins. The SureFire® technology is an exquisitely sensitive assay system which utilizes PerkinElmer’s ALPHA/Amplified Luminescent Proximity Homogeneous Assay detection chemistry. The SureFire® technology is widely employed by many of the world’s leading pharmaceutical and biotechnology companies in the development of new drugs and therapies for numerous diseases including cancer. The SureFire® range now includes over 60 SureFire® kits and is available exclusively through TGR’s commercial partner, PerkinElmer.

“The additional assays add to an already expansive and powerful array of existing cell based assay kits. We anticipate continued strong growth in the SureFire® portfolio as these assays meet a specific need in the market in providing the means to analyze endogenous levels of kinase activity in cells without the need for engineering recombinantly expressed proteins. The partnership with PerkinElmer has been an enormous success and brings together 2 innovative and powerful technologies in the combination of SureFire® and ALPHA,” says Leanna Read, CEO and Managing Director of TGR BioSciences.

About TGR BioSciences:

TGR BioSciences Pty Ltd (TGR) is a fast growing and innovative private biotechnology company based in Adelaide, South Australia, specializing in the development of drug discovery technologies and products to serve the global research and discovery markets for the Life Sciences. TGR provides the highest performing and sensitive cell based assays for analysis of GPCRs, kinases and cell signaling pathways to major pharmaceutical and biotechnology companies, and clients in government funded and academic laboratories worldwide. TGR has developed a broad portfolio of SureFire® assay kits, a state-of-the-art cell-based screening technology for high-throughput discovery and target identification of novel bioactives. SureFire® cellular kinase assays are available exclusively worldwide through our commercial partner PerkinElmer LAS. TGR is actively developing further novel cell based analysis technologies to advance research in areas such as oncology, neuroscience and key therapeutic areas.

For more information, please visit www.tgr-biosciences.com.au.

< | >